Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations.
Interleukin-6 (IL6) is believed to be involved in alterations of thyroid hormone metabolism in acute nonthyroidal illness. To evaluate the effects of IL6 on thyroid hormone metabolism in a chronic IL6-mediated disease, we measured thyroid hormone concentrations in multiple myeloma patients treated with intravenous anti-IL6 chimeric monoclonal antibodies ([cMabs] Kd = 6.25 x 10(-12) mol/L). Twelve patients were studied, receiving at least one complete treatment cycle of 14 days (daily dose: 5 mg, n = 3; 10 mg, n = 3; 20 mg, n = 3; and 40 mg, n = 3). Eight of them also completed a second treatment cycle of 14 days. Thyroid hormone concentrations were measured before, during, and after treatment with the anti-IL6 cMab. Even in the group with the lowest dosage, IL6 activity measured by the B9 bioassay was blocked completely. Compared with the reference ranges, 10 of 12 patients had one or more abnormal pretreatment values for thyroid hormone concentrations. Thyroid autoantibodies were negative in all patients. There was no correlation between thyroid hormone concentrations and IL6 levels, although plasma IL6 levels were increased in all but one subject. Moreover, neutralization of free IL6 by the anti-IL6 cMab did not affect thyroid hormone concentrations, although IL6-dependent C-reactive protein (CRP) levels decreased to undetectable levels in 11 of 12 patients. Two patients developed infectious complications resulting in increased free IL6 and CRP levels and in profound alterations of thyroid hormone levels consistent with an acute euthyroid sick syndrome. We conclude that IL6 is not a major determinant of thyroid hormone abnormalities in a chronic disease like multiple myeloma, but IL6 may be involved in thyroid hormone metabolism in acute diseases (probably in combination with other factors).
van Zaanen
H C
HC
Department of Hematology, University of Amsterdam, The Netherlands.
Romijn
J A
JA
Sauerwein
H P
HP
Lokhorst
H M
HM
Warnaar
S O
SO
Aarden
L A
LA
Endert
E
E
van Oers
M H
MH
D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D001681:Biological Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000276:immunology; D007262:Infusions, Intravenous; D015850:Interleukin-6 / Q000008:administration & dosage / Q000097:blood / Q000276:immunology*; D008297:Male; D051379:Mice; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000276:immunology / Q000503:physiopathology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology; D013963:Thyroid Hormones / Q000097:blood* / Q000276:immunology / Q000378:metabolism; D013972:Thyrotropin / Q000097:blood* / Q000276:immunology / Q000378:metabolism; D013974:Thyroxine / Q000097:blood / Q000276:immunology / Q000378:metabolism; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D015850:Interleukin-6; D011993:Recombinant Fusion Proteins; D013963:Thyroid Hormones; D014284:Triiodothyronine; D013972:Thyrotropin; D013974:Thyroxine